ViewPoint Therapeutics is a biotechnology company which develops treatments for diseases of protein misfolding, including cataracts. To address the need for new methods to treat cataracts and presbyopia, the Company is developing crystallin stabilizers, such as VP1-001, a molecule designed to stabilize the functional form of the crucial human lens protein alpha-crystallin against accumulated damage.